ReviewFrontiers in bioengineering and biotechnology2020
Regulation of Synthetic Biology: Developments Under the Convention on Biological Diversity and Its Protocols.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Functions and optimization of soft law in the international governance of synthetic biology: The predicament of hard law vs. the rise of soft law.Synthetic and systems biotechnology · 2026Article
- A comprehensive review of genomic-scale genetic engineering as a strategy to improve bacterial productivity.Microbiology (Reading, England) · 2025Review
- Regulatory framework for genetically modified organisms in the Kingdom of Eswatini.GM crops & food · 2024Review
- Post-release monitoring pathway for the deployment of gene drive-modified mosquitoes for malaria control in Africa.Malaria journal · 2024Article
- Advances and challenges in synthetic biology for mosquito control.Trends in parasitology · 2024Review
- [Improvement of the Approval System for the Development and Experimentation of Living Modified Organisms in Synthetic Biology].Jugan geon-gang gwa jilbyeong · 2023Review
- Epistemology of synthetic biology: a new theoretical framework based on its potential objects and objectives.Frontiers in bioengineering and biotechnology · 2023Article
- Regulation and management of the biosecurity for synthetic biology.Synthetic and systems biotechnology · 2022Article
- De novo synthesis of synthetic biology ecosystem in Slovakia: Challenges and opportunities.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- A Critical Review of the Current Global Ex Situ Conservation System for Plant Agrobiodiversity. II. Strengths and Weaknesses of the Current System and Recommendations for Its Improvement.Plants (Basel, Switzerland) · 2021Review
- Synthetic Biology: Old and New Dilemmas-The Case of Artificial Life.Biotech (Basel (Switzerland)) · 2021Article
- Advances in Synthetic Biology and Biosafety Governance.Frontiers in bioengineering and biotechnology · 2021Review
- Building a biofoundry.Synthetic biology (Oxford, England) · 2021Review
- Overstatements and Understatements in the Debate on Synthetic Biology, Bioterrorism and Ethics.Frontiers in bioengineering and biotechnology · 2021Article
- Adequacy and sufficiency evaluation of existing EFSA guidelines for the molecular characterisation, environmental risk assessment and post-market environmental monitoring of genetically modified insects containing engineered gene drives.EFSA journal. European Food Safety Authority · 2020Article
- The Importance of Biosecurity in Emerging Biotechnologies and Synthetic Biology.Avicenna journal of medical biotechnologyReview
- The Need for a Tiered Registry for US Gene Drive Governance.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary international forum deliberating the regulation of "synthetic biology" is the Convention on Biological Diversity (CBD), along with its subsidiary agreements concerned with the biosafety of living modified organisms (LMOs; Cartagena Protocol on Biosafety to the CBD), and access and benefit sharing in relation to genetic resources (Nagoya Protocol to the CBD). This discussion has been underway for almost 10 years under the CBD agenda items of "synthetic biology" and "new and emerging issues relating to the conservation and sustainable use of biological diversity," and more recently within the scope of Cartagena Protocol topics including risk assessment and risk management, and "digital sequence information" jointly with the Nagoya Protocol. There is no internationally accepted definition of "synthetic biology," with it used as an umbrella term in this forum to capture "new" biotechnologies and "new" applications of established biotechnologies, whether actual or conceptual. The CBD debates are characterized by polarized views on the adequacy of existing regulatory mechanisms for "new" types of LMOs, including the scope of the current regulatory frameworks, and procedures and tools for risk assessment and risk mitigation and/or management. This paper provides an overview of international developments in biotechnology regulation, including the application of the Cartagena Protocol and relevant policy developments, and reviews the development of the synthetic biology debate under the CBD and its Protocols, including the major issues expected in the lead up to and during the 2020 Biodiversity Conference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.